PubRank

Martina Rauner

Author PubWeight™ 39.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis. J Clin Invest 2013 2.48
2 The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol 2012 2.48
3 Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012 1.58
4 Osteoporosis: an age-related and gender-specific disease--a mini-review. Gerontology 2008 1.57
5 Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism 2010 1.25
6 miR-125b regulates calcification of vascular smooth muscle cells. Am J Pathol 2011 1.15
7 Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide. Haematologica 2013 1.05
8 Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 2006 0.98
9 Delayed bone regeneration and low bone mass in a rat model of insulin-resistant type 2 diabetes mellitus is due to impaired osteoblast function. Am J Physiol Endocrinol Metab 2011 0.98
10 Pathophysiology of osteoporosis. Wien Med Wochenschr 2009 0.95
11 Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013 0.94
12 Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol 2012 0.93
13 Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates. J Cell Biochem 2011 0.93
14 Regenerative potential of glycosaminoglycans for skin and bone. J Mol Med (Berl) 2011 0.91
15 Bone structure and metabolism in a rodent model of male senile osteoporosis. Exp Gerontol 2007 0.91
16 Skeletal and extraskeletal actions of denosumab. Endocrine 2012 0.90
17 Graves' disease after treatment with alemtuzumab for multiple sclerosis. Hormones (Athens) 2015 0.88
18 Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009 0.88
19 Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology 2014 0.87
20 The anti-progestin RU-486 inhibits viability of MCF-7 breast cancer cells by suppressing WNT1. Cancer Lett 2011 0.87
21 Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 2009 0.86
22 An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J 2011 0.85
23 High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients. BMC Cancer 2014 0.85
24 The osteoclast-associated receptor (OSCAR) is a novel receptor regulated by oxidized low-density lipoprotein in human endothelial cells. Endocrinology 2011 0.84
25 The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Biomaterials 2012 0.84
26 Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J Bone Miner Res 2013 0.84
27 Endocrine and clinical correlates of myostatin serum concentration in men--the STRAMBO study. J Clin Endocrinol Metab 2012 0.84
28 Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Res 2014 0.84
29 Osteomyelosclerosis, anemia and extramedullary hematopoiesis in mice lacking the transcription factor NFATc2. Haematologica 2011 0.83
30 Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int 2008 0.83
31 Clinical and endocrine correlates of circulating sclerostin levels in patients with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 2013 0.82
32 Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol 2011 0.82
33 WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo. J Bone Miner Res 2015 0.80
34 Bone morphogenetic proteins 2, 5, and 6 in combination stimulate osteoblasts but not osteoclasts in vitro. J Orthop Res 2010 0.80
35 Running has a negative effect on bone metabolism and proinflammatory status in male aged rats. Exp Gerontol 2008 0.79
36 The role of cathepsins in osteoimmunology. Crit Rev Eukaryot Gene Expr 2013 0.79
37 Early detection of bone metabolism changes under different antiepileptic drugs (ED-BoM-AED)--a prospective multicenter study. Epilepsy Res 2013 0.79
38 Monocytic expression of osteoclast-associated receptor (OSCAR) is induced in atherosclerotic mice and regulated by oxidized low-density lipoprotein in vitro. Biochem Biophys Res Commun 2013 0.78
39 Sulfated glycosaminoglycans support osteoblast functions and concurrently suppress osteoclasts. J Cell Biochem 2014 0.78
40 Differential effects of mixed lymphocyte reaction supernatant on human mesenchymal stromal cells. Exp Hematol 2012 0.77
41 The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation. Biomaterials 2013 0.77
42 Glycitein decreases the generation of murine osteoclasts and increases apoptosis. Wien Med Wochenschr 2010 0.75